Anavex Life Sciences Corp (AVXL)

[chrismiss_everyday]

onus probandi

The obligation to prove an assertion or allegation that one makes.

It’s been several years since I began investing in Anavex Life Sciences, and during that time there have been many assertions, such as: The CEO is unqualified to lead it! It’s formerly a printing company! Coffee would be a better treatment for Alzheimer’s! The CEO only exists to collect money while diluting shareholder value! The CEO’s hair is very unappealing! (Seriously?) The company doesn’t even know how to conduct clinical trials! There’s no peer review! Lincoln Partners fill-in-the-blank...

Meanwhile, the positive indications without deleterious side effects continue to add up for a growing number of patients who have enrolled in the studies. We have glimpses from time to time of positive progress resulting from the studies via news outlets, data releases via PR, and presentations to back up claims of not only stabilization, but improvements, in patients’ lives, AND coveted FDA fast track and orphan drug designations. The evidence is on our side.

There are imposed silences associated with trials, patient privacy, and legal proceedings, and we’re all eager for any and every scrap of information that can be offered up to piece together what’s to come, but from all the information thus far, we know the results to be beneficial, and in many cases those have been measurable and superlative to existing standards of care, or against no available treatments in some indications.

We’re on the cusp of seeing the SIGMACEPTOR™? platform come into full blossom under the direction of a qualified CEO and an excellent board of advisors who learned their way to the top.

There is a plethora of due diligence readily available thanks to many of the dedicated posters to this board gathering and gleaning on a regular basis. Many thanks to their combined expertise and enthusiasm and hope to cross paths with them (hopefully at the 2021 Annual Investor’s Conference!). GLTA.